ThermoGenesis Holdings, Inc. (NASDAQ:THMO – Free Report) – Research analysts at HC Wainwright dropped their Q3 2024 EPS estimates for shares of ThermoGenesis in a report issued on Tuesday, November 14th. HC Wainwright analyst S. Lee now expects that the company will post earnings per share of $0.02 for the quarter, down from their prior estimate of $0.03. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for ThermoGenesis’ current full-year earnings is ($3.26) per share. HC Wainwright also issued estimates for ThermoGenesis’ FY2024 earnings at $0.08 EPS.
ThermoGenesis Stock Down 17.9 %
Shares of THMO stock opened at $0.99 on Wednesday. ThermoGenesis has a 1 year low of $0.90 and a 1 year high of $6.75. The stock has a fifty day moving average price of $1.14 and a 200 day moving average price of $1.31.
Institutional Inflows and Outflows
ThermoGenesis Holdings, Inc develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market.
- Five stocks we like better than ThermoGenesis
- Canada Bond Market Holiday: How to Invest and Trade
- Left for dead, Tower Semiconductor is a phoenix rising
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 3 specialty apparel makers ready to spring higher
- What is the Australian Securities Exchange (ASX)
- Boeing’s future sealed as China resumes order flow
Receive News & Ratings for ThermoGenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ThermoGenesis and related companies with MarketBeat.com's FREE daily email newsletter.